IBDEI15T ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19721,2)
 ;;=^5002831
 ;;^UTILITY(U,$J,358.3,19722,0)
 ;;=E66.9^^84^921^43
 ;;^UTILITY(U,$J,358.3,19722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19722,1,3,0)
 ;;=3^Obesity,Unspec
 ;;^UTILITY(U,$J,358.3,19722,1,4,0)
 ;;=4^E66.9
 ;;^UTILITY(U,$J,358.3,19722,2)
 ;;=^5002832
 ;;^UTILITY(U,$J,358.3,19723,0)
 ;;=E74.39^^84^921^35
 ;;^UTILITY(U,$J,358.3,19723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19723,1,3,0)
 ;;=3^Intestinal Carbohydrate Absorption Disorder NEC
 ;;^UTILITY(U,$J,358.3,19723,1,4,0)
 ;;=4^E74.39
 ;;^UTILITY(U,$J,358.3,19723,2)
 ;;=^5002928
 ;;^UTILITY(U,$J,358.3,19724,0)
 ;;=E83.30^^84^921^46
 ;;^UTILITY(U,$J,358.3,19724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19724,1,3,0)
 ;;=3^Phosphorus Metabolism Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,19724,1,4,0)
 ;;=4^E83.30
 ;;^UTILITY(U,$J,358.3,19724,2)
 ;;=^5002997
 ;;^UTILITY(U,$J,358.3,19725,0)
 ;;=E83.51^^84^921^28
 ;;^UTILITY(U,$J,358.3,19725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19725,1,3,0)
 ;;=3^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,19725,1,4,0)
 ;;=4^E83.51
 ;;^UTILITY(U,$J,358.3,19725,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,19726,0)
 ;;=E83.52^^84^921^26
 ;;^UTILITY(U,$J,358.3,19726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19726,1,3,0)
 ;;=3^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,19726,1,4,0)
 ;;=4^E83.52
 ;;^UTILITY(U,$J,358.3,19726,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,19727,0)
 ;;=E87.5^^84^921^27
 ;;^UTILITY(U,$J,358.3,19727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19727,1,3,0)
 ;;=3^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,19727,1,4,0)
 ;;=4^E87.5
 ;;^UTILITY(U,$J,358.3,19727,2)
 ;;=^60041
 ;;^UTILITY(U,$J,358.3,19728,0)
 ;;=E89.2^^84^921^48
 ;;^UTILITY(U,$J,358.3,19728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19728,1,3,0)
 ;;=3^PostProcedural Hypoparathyroidism
 ;;^UTILITY(U,$J,358.3,19728,1,4,0)
 ;;=4^E89.2
 ;;^UTILITY(U,$J,358.3,19728,2)
 ;;=^5003037
 ;;^UTILITY(U,$J,358.3,19729,0)
 ;;=E89.6^^84^921^47
 ;;^UTILITY(U,$J,358.3,19729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19729,1,3,0)
 ;;=3^PostProcedural Adrenocortical Hypofunction
 ;;^UTILITY(U,$J,358.3,19729,1,4,0)
 ;;=4^E89.6
 ;;^UTILITY(U,$J,358.3,19729,2)
 ;;=^5003042
 ;;^UTILITY(U,$J,358.3,19730,0)
 ;;=L68.0^^84^921^25
 ;;^UTILITY(U,$J,358.3,19730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19730,1,3,0)
 ;;=3^Hirsutism
 ;;^UTILITY(U,$J,358.3,19730,1,4,0)
 ;;=4^L68.0
 ;;^UTILITY(U,$J,358.3,19730,2)
 ;;=^5009262
 ;;^UTILITY(U,$J,358.3,19731,0)
 ;;=M80.00XA^^84^921^2
 ;;^UTILITY(U,$J,358.3,19731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19731,1,3,0)
 ;;=3^Age-Related Osteoporosis w/ Fx,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,19731,1,4,0)
 ;;=4^M80.00XA
 ;;^UTILITY(U,$J,358.3,19731,2)
 ;;=^5013363
 ;;^UTILITY(U,$J,358.3,19732,0)
 ;;=M81.0^^84^921^3
 ;;^UTILITY(U,$J,358.3,19732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19732,1,3,0)
 ;;=3^Age-Related Osteoporosis w/o Fx
 ;;^UTILITY(U,$J,358.3,19732,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,19732,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,19733,0)
 ;;=M85.80^^84^921^44
 ;;^UTILITY(U,$J,358.3,19733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19733,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,19733,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,19733,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,19734,0)
 ;;=N62.^^84^921^24
 ;;^UTILITY(U,$J,358.3,19734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,19734,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,19734,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,19734,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,19735,0)
 ;;=E10.43^^84^921^6
